ReAlta Life Sciences Enhances Board with Noted Financial Executive

ReAlta Life Sciences, Inc., a clinical-stage biotech firm focused on mitigating life-threatening diseases through innovative inflammatory response therapies, has announced the addition of Emma Reeve to its Board of Directors. This strategic move aims to leverage Reeve's extensive global financial and operational experience within the life sciences sector to further ReAlta's mission and technological advancements.

Emma Reeve joins ReAlta with an impressive background, having accumulated over three decades of expertise in the pharmaceutical, medical device, and biotechnology industries. Her recent role was as Chief Financial Officer at Constellation Pharmaceuticals, Inc., an oncology-focused development-stage company, which was acquired by MorphoSys AG in 2021. Reeve was pivotal in leading Constellation’s initial public offering in 2018.

Prior to her tenure at Constellation, Reeve held the position of interim Chief Financial Officer and Corporate Controller at Parexel International, a global biopharmaceutical services firm. In this capacity, she managed comprehensive financial operations, investor relations, procurement, and facilities. Notably, she directed the financial aspects of a substantial $5 billion leveraged buy-out, transitioning Parexel to a privately held entity. Reeve's career also includes roles as Chief Financial Officer at Inotek Pharmaceuticals and Aton Pharma, as well as senior finance and operational positions at renowned companies such as Bristol Myers Squibb, Merck, and Novartis.

Currently, Emma Reeve serves as Chair of the Board at Editas Medicine and holds board positions at PTC Therapeutics and Aadi Bioscience, all public biotech enterprises. Additionally, she is a Board Director at Cardurion Pharma. Reeve earned her B.Sc. in computer science from Imperial College, University of London, and is an associate of the Institute of Chartered Accountants in England and Wales.

Buzz Heidt, Chairman of ReAlta’s Board, expressed enthusiasm over Reeve’s appointment, stating, “We are very pleased to welcome Emma Reeve to our Board of Directors. Her diverse experience and profound understanding of capital markets and financial strategies will be instrumental as ReAlta advances its programs towards global market launches. Emma's insights will undoubtedly enhance our efforts to bring novel therapies to patients in dire need.”

Reeve herself is eager to contribute to ReAlta’s mission, remarking, “I am impressed with the remarkable progress ReAlta has achieved in advancing multiple programs into the clinic. I am excited to take on this role and support the company’s objectives in addressing acute inflammatory and rare diseases.”

ReAlta Life Sciences is committed to saving lives by rebalancing the inflammatory response to tackle severe acute inflammatory and rare diseases. The company’s EPICC peptides, derived from research on the human astrovirus (HAstV-1), are designed to modulate complement and inflammatory processes. ReAlta's leading candidate, RLS-0071, has received clearance from the U.S. FDA for multiple indications, including the treatment of acute exacerbations of chronic obstructive pulmonary disease and acute graft-versus-host disease. It has also obtained Orphan Drug and Fast Track Designations for hypoxic-ischemic encephalopathy (HIE) from both the FDA and the European Medicines Agency.

Founded in 2018 and based in Norfolk, Virginia, ReAlta Life Sciences continues to innovate and push the boundaries of biotech to deliver life-saving treatments.